Peapod Lane Capital LLC Makes New $534,000 Investment in Kronos Bio, Inc. (NASDAQ:KRON)

Peapod Lane Capital LLC purchased a new stake in shares of Kronos Bio, Inc. (NASDAQ:KRON) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 562,620 shares of the company’s stock, valued at approximately $534,000.

Separately, Deltec Asset Management LLC purchased a new position in Kronos Bio during the fourth quarter worth about $190,000. 64.09% of the stock is currently owned by institutional investors and hedge funds.

Kronos Bio Trading Up 0.2 %

Shares of NASDAQ:KRON opened at $0.97 on Thursday. The company has a market capitalization of $58.54 million, a price-to-earnings ratio of -0.68 and a beta of 1.80. Kronos Bio, Inc. has a 12-month low of $0.69 and a 12-month high of $1.60. The business has a 50-day moving average price of $0.99 and a 200 day moving average price of $0.98.

Wall Street Analyst Weigh In

KRON has been the subject of several analyst reports. Piper Sandler cut shares of Kronos Bio from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $6.00 to $1.00 in a research note on Thursday, November 14th. TD Cowen cut Kronos Bio from a “buy” rating to a “hold” rating in a report on Thursday, November 14th.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.